TAS-114 is under clinical development by Taiho Pharmaceutical and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TAS-114’s likelihood of approval (LoA) and phase transition for Adenocarcinoma Of The Gastroesophageal Junction took place on 17 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 17 Jun 2022 decreased TAS-114’s LoA and PTSR for Gastric Cancer, decreased PTSR for Metastatic Colorectal Cancer, and decreased PTSR for Pancreatic Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TAS-114 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TAS-114 overview

TAS-114 is under development for the treatment of advanced solid tumors including metastatic non-small cell lung cancer, gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, advanced and pancreatic cancer. It is administered orally. The drug candidate is an antimetabolite small molecule inhibitor of deoxyuridine 5'-triphosphate nucleotidehydrolase (dUTPase) and dihydropyrimidine dehydrogenase (DPD). It was also under development for cervical cancer.

Taiho Pharmaceutical overview

Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, allergy, immunology and urology. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as herbal digestive medicine, topical analgesics, antifungal cream and herbal medicine powder, among others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries situated worldwide including Japan, China, Canada, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.

Quick View TAS-114 LOA Data

Report Segments
  • Innovator
Drug Name
  • TAS-114
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.